The Scleroderma Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Scleroderma Market:
https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report
According to The Business Research Company’s Scleroderma Global Market Report 2024, The scleroderma market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to $2.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to advances in diagnosis, immunological research, therapeutic developments, awareness and education, genetic studies.
The scleroderma market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to biological therapies, precision medicine, stem cell therapies, genomic and biomarker research, global collaborations. Major trends in the forecast period include digital health solutions, focus on microbiome, patient-centric care, regenerative medicine, health equity and access.
The greater prevalence of scleroderma is driving the scleroderma market going forward. Scleroderma is a chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of skin and other tissues. An unregulated immune response, possibly triggered by various environmental factors, leads to the development of this condition. As the number of cases rises, the importance of improved diagnosis and treatment becomes evident. Scleroderma therapeutics are crucial to managing illness and alleviating symptoms by regulating the immune response and mitigating exposure to environmental risk factors. For instance, in June 2022, according to Karger Publishers, a Switzerland-based publisher of peer-reviewed journals, 19,000 people had scleroderma in the UK and 2.5 million people worldwide. Furthermore, in July 2021, a research article published by Oxford Academic Press, a university press affiliated with the University of Oxford in the UK, revealed that the global prevalence of scleroderma was 17.6 cases per 100,000 people and the incidence rate was 1.4 cases per 100,000 person-years. As a result, the greater prevalence of scleroderma is driving the scleroderma market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12615&type=smp
The scleroderma market covered in this report is segmented –
1) By Treatment: Medication, Surgery, Other Treatments
2) By Indication: Systemic Scleroderma, Localized Scleroderma
3) By End User: Hospital, Pharmaceutical Stores, Other End User
Developing novel treatments is a key trend gaining popularity in the scleroderma market. Major companies in the scleroderma market are developing novel drugs to manage the symptoms and sustain their position in the market. For instance, in April 2022, Tyr Pharma Inc., a US-based biotherapeutics manufacturer, received regulatory approval for its novel systemic sclerosis-related interstitial lung disease drug efzofitimod from the US Food and Drug Administration, a US-based health regulatory agency. The new drug is a First-in-class immunomodulator to downregulate and control the immune response by modulating the neuropilin-2 (NRP2) receptor to reduce symptoms of scleroderma. Additionally, Efzofitimod also targets the same immune cells responsible for the pathology of SSc-ILD (interstitial lung disease associated with systemic sclerosis) and pulmonary sarcoidosis, leading to reduced pro-inflammatory markers in a clinical study with patients suffering from pulmonary sarcoidosis.
The scleroderma market report table of contents includes:
.
.
.
Top Major Players:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Overview and Scope Boxing gloves refer to the cushioned gloves worn by boxers during fights…
Overview and Scope Wagyu beef refers to a Japanese beef cattle breed modified from Asian…
Overview and Scope Air care refers to the products that improve the indoor environment by…
Overview and Scope A golf club refers to sports equipment used in golf that is…
Overview and Scope Clinical biomarkers refer to quantifiable biological traits identifying normal or diseased bodily…
Overview and Scope A cable tray is a mechanical support structure that offers a rigid…